All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
This is the H-2Db restricted epitope derived from the lymphocytic choreomeningitis virus (LCMV) glycoprotein gp 33; residues 33 to 41.
Loading...
| CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
| TCR-L034 | Human anti-gp33 (KAVYNFATM) T Cell Receptor, pMSGV1 | LCMV | Human | KAVYNFATM | retroviral vector | |||
| TCR-L035 | Human anti-gp33 (KAVYNFATM) T Cell Receptor, pMP71 | LCMV | Human | KAVYNFATM | retroviral vector | |||
| TCR-L036 | Mouse anti-gp33 (KAVYNFATM) T Cell Receptor, pMP71 | LCMV | Mouse | KAVYNFATM | retroviral vector | |||
| TCR-L034Z | Human anti-gp33 T cell receptor, pCDTCR1 | LCMV | Human | KAVYNFATM | Lentiviral | |||
| TCR-L035Z | Human anti-gp33 (aa1-9) T cell receptor, pCDTCR1 | LCMV | Human | KAVYNFATM | Lentiviral | |||
| TCR-L036Z | Mouse anti-gp33 (aa1-9) T cell receptor, pCDTCR1 | LCMV | Mouse | KAVYNFATM | Lentiviral | |||
| TCR-C084Z | Mouse anti-gp33 (CB-T54), pCDTCR1 | LCMV | CB-T54 | Mouse | KAVYNFATC | H-2Db | Lentiviral | |
| TCR-C085Z | Mouse anti-gp33 (CB-T55), pCDTCR1 | LCMV | CB-T55 | Mouse | KAVYNFATM | H-2Db | Lentiviral | |
| TCR-L259 | Mouse anti-gp33 T cell receptor (CB-T53), pCDTCR1 | LCMV | CB-T53 | Mouse | EQKLISEEDL | HLA-A2 | Lentiviral | |
| TCR-YC0510 | Mouse anti-gp33 T cell receptor ((P14)-1), pCDTCR1 | P14 | Mouse | KAVANFATM | H2-Db | Lentiviral vector | ||
| TCR-YC0511 | Mouse anti-gp33 T cell receptor ((P14)-2), pCDTCR1 | P14 | Mouse | KAVFNFATM | H2-Db | Lentiviral vector | ||
| TCR-YC0512 | Mouse anti-gp33 T cell receptor ((P14)-3), pCDTCR1 | P14 | Mouse | KAVSNFATM | H2-Db | Lentiviral vector |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION